Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.

Abstract

Currently, nine protease inhibitors (PIs) are available in the U.S.1–9 As of October 2010, the FDA had given tentative approval to manufacturers to produce generic versions of atazanavir (Reyataz, ATV, Bristol-Myers Squibb) and lopinavir/ritonavir (Kaletra, LPV/r, Abbott). PIs are often an essential component of highly active antiretroviral (ARV) therapy (HAART) in the fight to control the progression of human immunodeficiency virus type-1 (HIV-1) infection. HAART generally refers to a combination of at least three ARV agents with activity against a particular virus. In combination with other ARV agents, PIs help to achieve the primary goals of HIV treatment, which include suppressing the viral load, reducing morbidity, maximizing survival, improving quality of life, restoring and maintaining immunological function, and preventing further disease transmission.10 This article compares commonly used ARV agents in the PI class, with a focus on their efficacy and safety.